TY - JOUR
T1 - Characterization of the evolutionary and virological aspects of mutations in the receptor binding motif of the SARS-CoV-2 spike protein
AU - Masuda, Yuuka
AU - Nasser, Hesham
AU - Zahradnik, Jiri
AU - Mitoma, Shuya
AU - Shimizu, Ryo
AU - Nagata, Kayoko
AU - Takaori-Kondo, Akifumi
AU - Schreiber, Gideon
AU - Shirakawa, Kotaro
AU - Saito, Akatsuki
AU - Ikeda, Terumasa
AU - Ito, Jumpei
AU - Sato, Kei
N1 - We would like to thank all members belonging to The Genotype to Phenotype Japan (G2P-Japan) Consortium. We thank Dr. Kenzo Tokunaga (National Institute for Infectious Diseases, Japan) and Dr. Jin Gohda (The University of Tokyo, Japan) for providing reagents. We gratefully acknowledge all data contributors, i.e. the Authors and their Originating laboratories responsible for obtaining the specimens, and their submitting laboratories for generating the genetic sequence and metadata and sharing via the GISAID Initiative, on which this research is based. The super-computing resource was provided by the Human Genome Center at The University of Tokyo. Funding: The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers “UTOPIA” (JP223fa627001, to KSa), AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP223fa727002, to KSa); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108574, to HN; JP21fk0108465, to AS; JP22fk0108146, to KSa; JP21fk0108494 to G2P-Japan Consortium, TI and KSa; JP21fk0108425, to KSa; JP21fk0108432, to KSa; JP22fk0108534, to TI, and KSa; JP22fk0108511, to TI and KSa); AMED Research Program on HIV/AIDS (JP22fk0410033, to AS; JP22fk0410047, to AS; JP22fk0410055, to TI; and JP22fk0410039, to KSa); AMED CRDF Global Grant (JP22jk0210039 to AS); AMED Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0325009, to AS); JST PRESTO (JPMJPR22R1, to JI); JST CREST (JPMJCR20H4, to KSa); JSPS KAKENHI Grant-in-Aid for Scientific Research C (22K07103, to TI); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (22K16375, to HN; 20K15767, JI); JSPS Core-to-Core Program (A. Advanced Research Networks) (JPJSCCA20190008, to KSa); JSPS Leading Initiative for Excellent Young Researchers (LEADER) (to TI); International Joint Research Project of the Institute of Medical Science, the University of Tokyo (to TI, JZ, and AS); The Tokyo Biochemical Research Foundation (to KSa); Takeda Science Foundation (to TI); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to TI); The Naito Foundation (to TI); and the project of National Institute of Virology and Bacteriology, Programme EXCELES, funded by the European Union, Next Generation EU (LX22NPO5103, to JZ).
PY - 2023/12/22
Y1 - 2023/12/22
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has substantially diversified during the pandemic, resulting in the successive emergence of variants characterized by various mutations. It has been observed that several epidemic variants, including those classified as variants of concern, share mutations at four key residues (L452R, T478K, E484K, and N501Y) within the receptor binding motif (RBM) region of the spike protein. However, the processes through which these four specific RBM mutations were acquired during the evolution of SARS-CoV-2, as well as the degree to which they enhance viral fitness, remain unclear. Moreover, the effect of these mutations on the properties of the spike protein is not yet fully understood. In this study, we performed a comprehensive phylogenetic analysis and showed that the four RBM mutations have been convergently acquired across various lineages throughout the evolutionary history of SARS-CoV-2. We also found a specific pattern in the order of acquisition for some of these mutations. Additionally, our epidemic dynamic modeling demonstrated that acquiring these mutations leads to an increase in the effective reproduction number of the virus. Furthermore, we engineered mutant spike proteins with all feasible combinations of the four mutations, and examined their properties to uncover the influence that these mutations have on viral characteristics. Our results provide insights into the roles these four mutations play in shaping the viral characteristics, epidemic proliferation, and evolutionary pathway of SARS-CoV-2.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has substantially diversified during the pandemic, resulting in the successive emergence of variants characterized by various mutations. It has been observed that several epidemic variants, including those classified as variants of concern, share mutations at four key residues (L452R, T478K, E484K, and N501Y) within the receptor binding motif (RBM) region of the spike protein. However, the processes through which these four specific RBM mutations were acquired during the evolution of SARS-CoV-2, as well as the degree to which they enhance viral fitness, remain unclear. Moreover, the effect of these mutations on the properties of the spike protein is not yet fully understood. In this study, we performed a comprehensive phylogenetic analysis and showed that the four RBM mutations have been convergently acquired across various lineages throughout the evolutionary history of SARS-CoV-2. We also found a specific pattern in the order of acquisition for some of these mutations. Additionally, our epidemic dynamic modeling demonstrated that acquiring these mutations leads to an increase in the effective reproduction number of the virus. Furthermore, we engineered mutant spike proteins with all feasible combinations of the four mutations, and examined their properties to uncover the influence that these mutations have on viral characteristics. Our results provide insights into the roles these four mutations play in shaping the viral characteristics, epidemic proliferation, and evolutionary pathway of SARS-CoV-2.
UR - http://www.scopus.com/inward/record.url?scp=85191718017&partnerID=8YFLogxK
U2 - 10.3389/fviro.2023.1328229
DO - 10.3389/fviro.2023.1328229
M3 - مقالة
SN - 2673-818X
VL - 3
JO - Frontiers in Virology
JF - Frontiers in Virology
M1 - 1328229
ER -